MIRM · Mirum Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$93.99
+0.66 (+0.71%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$6.14B
Shares
65.28M
Volume · Nov 13
331.08K
Avg daily vol (3M)
680.13K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Mirum Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Mirum Pharmaceuticals, Inc. (MIRM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
Mirum Pharmaceuticals, Inc. (MIRM) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-11
Mirum Pharmaceuticals, Inc. (MIRM) November 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-10
Mirum Pharmaceuticals, Inc. (MIRM) November 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-03
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript
Revenue
$185.72M
▲ 39.6% YoY Diluted EPS
$-0.87
▼ 1840% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-16
Mirum Pharmaceuticals, Inc. (MIRM) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-15
Mirum Pharmaceuticals, Inc. (MIRM) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-10
Mirum Pharmaceuticals, Inc. (MIRM) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
Positive tone
Velixabat PSC/VISTA regulatory delay
Velixabat PBC/Vantage study
Commercial sales and guidance raise
Revenue
$176.24M
▲ 37.9% YoY Diluted EPS
$-1.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-20
Mirum Pharmaceuticals, Inc. (MIRM) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Mirum Pharmaceuticals, Inc. (MIRM) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
Confident tone
ZalurgoCertid / FOP licensing
Rare liver disease pipeline (PSC, hepatitis delta)
Livmarly / PFIC commercial performance
Revenue
$159.88M
▲ 43.3% YoY Diluted EPS
$-13.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
Confident tone
Pipeline and registrational readouts
Volixibat VISTA study in PSC
Pediatric cholestatic expansion (EXPAND)
Revenue
$148.93M*
▲ 49.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call Transcript
Confident tone
LIVMARLI franchise (Alagille and PFIC)
Volixibat VISTAS Phase IIb in PSC
Pipeline expansion (EXPAND, MRM-3379 in Fragile X)
Revenue
$133.01M
▲ 47.2% YoY Diluted EPS
$0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript
Confident tone
Livmarli U.S. performance (PFIC, Alagille, new formulation)
Volixibat VISTAS Phase IIb in PSC
International Livmarli expansion (Europe, Japan via Takeda)
Revenue
$127.78M
▲ 64.1% YoY Diluted EPS
$-0.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript
Confident tone
LIVMARLI performance and tablet launch
Pipeline: Volixibat VISTAS in PSC
Pipeline: Volixabat VANTAGE in PBC and EASL data
Revenue
$111.58M
▲ 61.2% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript
Confident tone
OCA competition in PBC
Livmarly EXPAND study (broader cholestatic pruritus)
2025 financial guidance
Revenue
$99.41M*
▲ 42.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript
Confident tone
LIVMARLI commercial growth
Volixibat pipeline (PBC/PSC)
CHENODAL/CTX PDUFA
Revenue
$90.38M
▲ 89.4% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call
Revenue
$77.88M
▲ 107.7% YoY Diluted EPS
$-0.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript
Confident tone
PFIC label expansion
Volixibat interim analysis
LIVMARLI commercial growth
Revenue
$69.22M
▲ 119.1% YoY Diluted EPS
$-0.54
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript
Confident tone
LIVMARLI commercial growth
Volixibat pipeline (VISTAS/VANTAGE)
2024 financial guidance
Revenue
$69.55M*
▲ 149.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript
Revenue
$47.73M
▲ 154.1% YoY Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2023 Earnings Call Transcript
Revenue
$37.50M
▲ 114.5% YoY Diluted EPS
$-1.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2023 Earnings Call Transcript
Revenue
$31.60M
▲ 145.1% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Call Transcript
Revenue
$27.91M*
▲ 789.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2022 Earnings Call Transcript
Revenue
$18.78M
▲ 275.6% YoY Diluted EPS
$-1.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2022 Earnings Call Transcript
Revenue
$17.48M
▲ 58.9% YoY Diluted EPS
$-0.84
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2022 Earnings Call Transcript
Revenue
$12.89M
Diluted EPS
$-1.17
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-09
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2021 Earnings Call Transcript
Revenue
$3.14M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2021 Earnings Call Transcript
Revenue
$5.00M
Diluted EPS
$-1.55
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2021 Earnings Call Transcript
Revenue
$11.00M
Diluted EPS
$-1.45
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2021 Earnings Call Transcript
Revenue
$0
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Showing 1–31 of 31 webcasts
Key facts
CIK
1759425
CUSIP
604749101
13F (30d)
243 filings
219 filers
Visit website
Investor relations